Common Deficiencies For Study Sample Reanalysis In Pk Be For Andas Bioanalysis 2020

Summary

Tian Ma, CDER Office of Generic Drugs, summarize Zhen Zhang, CDER Office of Generic Drugs, explains how to identify challenges in establishing bioequivalence (BE) of drug ... Ruben Ayala, CDER Office Translational Sciences, discusses Arindam Dasgupta, Deputy Director, Division of New Drug Zhen Zhang and Tian Ma from the CDER Office of Generic Drugs respond to audience questions. FDA CDER's Small Business ... Diaa Shakleya, CDER Office of Pharmaceutical Quality (OPQ), discusses Liangfeng Han from the Office of Generic Drugs discusses the potential of, and challenges with, using Drs. Leah Falade and Suman Dandamudi from CDER's Office of Generic Drugs discuss what to expect during FDA Biobank best practices for nucleic acid quality control Ensure your biobank is putting its best Jinhui Zhang, CDER Office of Pharmaceutical Quality, discusses the Biologics Price Competition and Innovation Act (BPCI) Act ... Thank you jyros for uh inviting me here uh to present and uh also